Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy

Ichiro Maruko; Hideki Koizumi; Taiji Hasegawa; Hisaya Arakawa; Tomohiro Iida

doi:10.1371/journal.pone.0184112

Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy

PLoS One. 2017 Aug 29;12(8):e0184112. doi: 10.1371/journal.pone.0184112. eCollection 2017.

Authors

Ichiro Maruko¹, Hideki Koizumi¹, Taiji Hasegawa¹, Hisaya Arakawa¹, Tomohiro Iida¹

Affiliation

¹ Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Shinjuku, Tokyo, Japan.

Abstract

Purpose: To compare the efficacy of the subthreshold micropulse laser (SML) to conventional laser (CL) in treating focal leakages of the retinal pigment epithelium (RPE) in the eyes with central serous chorioretinopathy (CSC).

Methods: Twenty-nine eyes of 28 patients with CSC and typical focal leakage were treated with CL or SML. Both treatments were made with a 577 nm yellow laser (CL: NIDEK MC-500, SML: IRIDEX IQ577). The percentage of eyes with a complete resolution, the distance of the laser burns from the fovea, and injury of the RPE after treatment were studied.

Results: A complete resolution was seen in 10 of 15 eyes (66.7%) after CL and 9 of 14 eyes (64.3%) after SML (P = 0.89). The average distance from the foveal center to the leakage point was 1282±596 μm for eyes treated with CL and 1271±993 μm for eyes treated with SML (P = 0.4). Only three eyes treated with SML had treatment sites within 500 μm of the fovea. RPE damage determined by fundus autofluorescence was found in all eyes treated with CL and only one eye treated with SML (P<.01).

Conclusions: SML achieved equivalent therapeutic effects as CL but without RPE damage in eyes with CSC.

MeSH terms

Adult
Central Serous Chorioretinopathy / diagnostic imaging
Central Serous Chorioretinopathy / surgery*
Female
Humans
Laser Coagulation
Laser Therapy / methods*
Male
Middle Aged
Retrospective Studies
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity / physiology

Grants and funding

Dr. Maruko reports grants from JSPS KAKENHI (Grant Number JP16K11274), grants and personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Santen Pharmaceutical Inc., personal fees from Alcon Japan, Ltd., personal fees from Topcon Co., Ltd., personal fees from Senju Pharmaceutical Co., Ltd., personal fees from NIDEK Co., Ltd., outside the submitted work. Dr. Koizumi reports grants and personal fees from Novartis Pharma K.K., personal fees from Bayer Yakuhin, Ltd., personal fees from Santen Pharmaceutical Inc., personal fees from Alcon Japan, Ltd., personal fees from Topcon Co., Ltd., personal fees from Senju Pharmaceutical Co., Ltd., personal fees from HOYA Corp., personal fees from Canon Inc., personal fees from Wakamoto Pharmaceutical Co., Ltd., personal fees from NIDEK Co., Ltd., outside the submitted work;. Dr. Hasegawa has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Iida reports grants and personal fees from Novartis Pharma K.K. (Japan), personal fees from Bayer Yakuhin, Ltd. (Japan), grants and personal fees from Santen Pharmaceutical Co., Ltd. (japan), grants from Nidek, research support from Chuosangyo (Japan), outside the submitted work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.